Core Insights - nDatalyze Corp. has achieved a significant development milestone for its AI-driven sports performance analytics platform, Epitome, by completing data collection, testing, and calibration across three organized hockey teams [1] - The dataset includes athletes from two Western Hockey League teams and one Ontario University Athletics program, allowing for a comprehensive analysis across different competitive environments [1] - The completion of this milestone reduces technical risk and enables the company to shift focus from platform development to market analysis and commercialization planning [1] Platform Overview - Epitome is designed as a decision-support analytics platform that integrates machine learning with biological, emotional, and environmental data to create individualized athlete profiles, known as "Signatures" [1][3] - The platform aims to support personalized player development strategies, workload management, and organizational decision-making, rather than predicting specific athletic outcomes [1] Milestone Significance - The completion of multi-team data collection and calibration is seen as a validation step for the Epitome platform, demonstrating the consistency of the analytics framework across independent organizations [2][4] - This milestone reduces bias associated with single-team and single-environment data, supporting controlled expansion to additional teams and development pathways [4] Next Steps - Following the completion of data collection and calibration, the company will focus on identifying and quantifying addressable market segments, including specialized hockey academies, junior teams, athlete parents, and scouts [2] - This will form the basis for a data-driven marketing and sales strategy aimed at commercialization [2]

Core Insights - nDatalyze Corp. has launched "Epitome," a sports performance analytics project utilizing advanced machine learning to enhance professional hockey performance, tapping into a global sports analytics market projected to exceed USD $22 billion by 2030 [1][2] Value Proposition - Epitome employs proprietary biometric modeling technology to predict athletic performance, addressing a significant challenge in professional sports that could reduce risks and enhance returns for NHL franchises [2] - The project positions nDatalyze at the intersection of AI, genomics, and sports analytics, creating substantial commercial potential [2] Industry Demand & Economic Rationale - The inefficiencies in player drafting and development are highlighted, with only 19% of NHL draftees playing over 200 games, leading to significant financial losses [4] - The project aims to de-risk multimillion-dollar decisions in player selection by adapting clinically studied algorithms for sports applications [4] Progress & Strategic Positioning - Epitome reflects nDatalyze's commitment to commercializing its AI-driven biometric technology across high-value sectors, targeting a multi-billion dollar market with a clinically grounded solution [5] - The initiative is expected to deliver meaningful shareholder value and establish the company as a leader in predictive sports performance analytics [5] Signature Modeling - Epitome creates a unique "Signature" for each player by integrating biometric data, performance statistics, genetic predispositions, and algorithmic scores [6] - The system benchmarks individual Signatures against those of proven high-performance players to establish predictive metrics [6] - Applications include assessing future performance prospects, optimizing roster configurations, and developing personalized coaching protocols [6] Project Support and Financing - nDatalyze has secured commitments from three advisors, including former NHL coaches, to define the digital "high-performance player" [7] - The project is fully financed through existing cash, ensuring no dilution to shareholders at this stage [7] - Epitome is included in the proposed spinout related to the previously announced RTO, benefiting pre-RTO shareholders regardless of the RTO's closure [7]